Eric Dube, Ph.D., serves as the President, Chief Executive Officer, and Director at Travere Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Dr. Dube has been instrumental in leading Travere Therapeutics since joining the company, bringing a wealth of experience and expertise to his role. Prior to his appointment at Travere, he held various leadership positions in the biopharmaceutical industry, demonstrating his commitment to advancing treatments for complex medical conditions. Dr. Dube's professional background is marked by significant achievements in drug development and commercialization. Before joining Travere Therapeutics, he served in senior roles at companies such as Amgen and Avanir Pharmaceuticals, where he contributed to the successful development and launch of several innovative therapies. His strategic vision and leadership have been pivotal in guiding Travere Therapeutics through critical phases of growth and expansion. Under his leadership, the company has made substantial progress in its mission to deliver life-altering therapies to patients with rare diseases, notably advancing its pipeline and strengthening its market presence. As President, CEO, and Director at Travere Therapeutics, Dr. Dube is responsible for overseeing the company's overall strategy and operations. His role encompasses driving the development of new treatments, managing the company's portfolio, and fostering a culture of innovation and excellence. Dr. Dube's dedication to improving patient outcomes and his ability to navigate the complexities of the biopharmaceutical industry make him a vital leader at Travere Therapeutics. His contributions continue to shape the company's future, positioning it as a leader in the rare disease therapeutic space.